Readystate Asset Management’s iTeos Therapeutics ITOS Stock Holding History

Readystate Asset Management’s Portfolio ITOS Stock Details ITOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-17,040	Closed	-$102K	–	771
2025 Q1	$102K	Sell	17,040 -26,114	-61%	-$192K	﹤0.01%	582
2024 Q4	$331K	Sell	43,154 -126,665	-75%	-$1.09M	0.01%	541
2024 Q3	$1.73M	Buy	169,819 +83,700	+97%	+$1.28M	0.03%	372
2024 Q2	$1.28M	Sell	86,119 -100,783	-54%	-$1.44M	0.04%	286
2024 Q1	$2.55M	Buy	186,902 +45,111	+32%	+$491K	0.04%	505
2023 Q4	$1.55M	Buy	141,791 +36,100	+34%	+$358K	0.05%	324
2023 Q3	$1.16M	Buy	105,691 +17,300	+20%	+$221K	0.06%	298
2023 Q2	$1.17M	Buy	+88,391	New	+$1.26M	0.09%	173

Other funds holding ITOS

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Readystate Asset Management's ITOS Position: Q2 2025 in Review

Readystate Asset Management sold out of iTeos Therapeutics (ITOS) in Q2 2025, closing a stake of 17,040 shares — an estimated $102K sold.

Readystate Asset Management first reported a position in ITOS in Q2 2023 and held it in 8 quarters. The position peaked at $2.55M in Q1 2024. 136 funds tracked by Wall St. Rank hold ITOS as of Q2 2025.

Readystate Asset Management reported no remaining iTeos Therapeutics position as of Q2 2025 after selling out during the quarter.
Readystate Asset Management sold 17,040 iTeos Therapeutics shares in Q2 2025, an estimated $102K.
Readystate Asset Management first reported a position in iTeos Therapeutics in Q2 2023 and held it in 8 quarters.
Readystate Asset Management's iTeos Therapeutics position peaked at $2.55M in Q1 2024.
136 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q2 2025.

Based on Readystate Asset Management's 13F filing for Q2 2025, filed 7 Aug 2025.